Millennium Management LLC Has $7.99 Million Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Millennium Management LLC boosted its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 91.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 424,137 shares of the company's stock after purchasing an additional 202,419 shares during the period. Millennium Management LLC owned about 0.56% of Nurix Therapeutics worth $7,991,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. US Bancorp DE raised its stake in shares of Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after acquiring an additional 842 shares during the last quarter. Aquatic Capital Management LLC bought a new position in Nurix Therapeutics in the 4th quarter valued at $87,000. Summit Investment Advisors Inc. boosted its stake in Nurix Therapeutics by 13.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock worth $138,000 after purchasing an additional 877 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Nurix Therapeutics during the fourth quarter worth $164,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Nurix Therapeutics in the fourth quarter valued at $207,000.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Leerink Partners initiated coverage on shares of Nurix Therapeutics in a research report on Monday, March 17th. They set a "market perform" rating and a $16.00 price target on the stock. Stifel Nicolaus decreased their price objective on Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Wall Street Zen lowered Nurix Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Leerink Partnrs upgraded shares of Nurix Therapeutics to a "hold" rating in a report on Monday, March 17th. Finally, Wells Fargo & Company cut their price target on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $30.44.

Nurix Therapeutics Stock Down 1.0%

Shares of NASDAQ:NRIX traded down $0.11 during mid-day trading on Friday, reaching $10.53. 135,312 shares of the stock were exchanged, compared to its average volume of 864,462. The company has a market cap of $802.69 million, a P/E ratio of -3.64 and a beta of 2.23. The stock's 50 day simple moving average is $10.39 and its 200-day simple moving average is $15.91. Nurix Therapeutics, Inc. has a one year low of $8.18 and a one year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.05. The company had revenue of $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same period last year, the business earned ($0.76) EPS. Analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Insider Activity at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 5,825 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now owns 33,724 shares in the company, valued at $488,660.76. This trade represents a 14.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $38,835.50. Following the transaction, the insider now owns 61,516 shares of the company's stock, valued at $707,434. The trade was a 5.20% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,838 shares of company stock valued at $221,500. Corporate insiders own 7.40% of the company's stock.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.